In 1972, I took over the Kurpfalzkrankenhaus of the ``Stiftung Rehabilitation'' in Heidelberg, a hospital for internal medicine and neurology that was then newly constructed. At that time it was still called ``Rehabilitationsklinik Heidelberg.'' The university hospital for internal medicine offered me the opportunity to take a part of the hemophilia treatment with me to the new hospital. So, I founded the supraregional Hemophilia Center Heidelberg and soon had more than 100 persons with hemophilia as my patients. Already in 1972, a factor (F) VIII concentrate of higher purity was available. However, this concentrate was still in somewhat short supply. It could be infused in shorter time and did not have to be infused as slowly as usual. One of my patients, who underwent his vocational training nearby, never came to see me for treatment between his classes when he had an acute joint bleeding but only after, and then it was virtually too late. He did not want to miss a lecture. Once we had the new concentrate, which could be infused more quickly, he came for treatment during his 15-minute break between classes. That was the beginning of early treatment. Moreover, this concentrate enabled us to give our patients sufficient replacement therapy, what at least we considered to be sufficient, and also allowed us to begin to introduce self-treatment. However, this also meant that we stopped using cryoprecipitate from only a few donations but began using concentrates that were manufactured from larger plasma pools from many donors. To translate ``pool,'' the German dictionary also allows us to use ``Tümpel,'' which is a very small and dirty pond, for it came to light that these ``Tümpels'' were contaminated by viruses. In this context, I must express myself correctly, for the cryoprecipitates were also ``Tümpel.'' Therefore, we had to warn all patients about hepatitis before infusing the concentrate. After using concentrates for 1 year I looked into the clinical records of 114 patients and found that during the year, 17 of them (15%) had developed infectious jaundice. This corresponded with findings in the international literature (Table [1]).[1] [2] [3] [4] [5] [6] [7] [8] The average incubation period after beginning intensive replacement therapy was 46 days (Table [2]).[8] It was believed that this was an indication of non-A, non-B (NANB) hepatitis. Until the onset of jaundice, the average amount of concentrate that had been infused was 10,827 units, with considerable variations in amounts (Table [3]).[8]